Renier Heijkants
Lead Scientist Byondis
Renier Heijkants academic career spanned DNA repair, genetics and molecular biology, with a strong emphasis on translational cancer research. He earned his PhD at Leiden University focusing on the MDMX protein, a key regulator of the tumor suppressor p53, and its role in melanoma progression and therapy resistance. Following this he aimed to apply molecular biological knowledge to develop novel payload and ADC formats. In his current position as lead scientist at Byondis Renier is leading a group of scientists contributing to novel ADC platform development at Byondis at a preclinical stage.
Seminars
Tuesday 24th February 2026
Showcasing Preclinical Development of Byondis’ Antifolate Linker-Drug ADCs
12:00 pm
- Presenting the development of a novel antifolate linker-drug platform, a toxin class with a clinically validated mechanism of action
- Discussing preclinical development of antifolate-based ADCs across in vitro and in vivo studies
- Outlining antifolate payload mechanism of action and physicochemical properties
